AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06678971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basket-Up
Description: The Basket-Up warm-up program is developed by a committee of experts, including the medical staff and the Performance Department of Valencia Basket Club, with detailed information previously published. This protocol is specifically designed to address the physiological, functional, and physical demands of basketball training. Like the FIFA 11+ program, it is structured into three phases with progressively increasing levels of difficulty, lasting a total of 20 minutes.~Phase 1 includes three exercises aimed at improving mobility. Phase 2 features six exercises focused on strength, direction changes, and plyometric activities. Phase 3 consists of six exercises designed to enhance agility and neurocognitive skills.
Study NCT04959695 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PE Coach
Description: PE Coach is a treatment companion mobile application designed with features to support the tasks of prolonged exposure psychotherapy and the homework between sessions.
Study NCT04959695 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure without PE Coach
Description: Standard PE treatment protocol without PE Coach
Study NCT06617923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Senaparib
Description: Participants will receive orally 80mg daily Days 1-28 of a 28 day cycle.
Study NCT06617923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will receive orally 20mg daily Days 1-21 of a 28 day cycle.
Study NCT06085131 — intervention group
Intervention type: DEVICE
Intervention: Argos
Description: Argos Biometer
Study NCT06615557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasedienol Nasal Spray
Description: Nasal spray delivered 20 minutes before the PSC
Study NCT06615557 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Nasal Spray
Description: Nasal spray delivered 20 minutes before the PSC
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986393
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Specified dose on specified days
Study NCT06615479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Specified dose on specified days
Study NCT06251661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive multi-sensory Rehabilition
Description: Kinetic awareness: Initially, only one joint will be moved at a time. Then the therapist will reposition the joint and ask the participants to report their perception of the joint position. Initially, the participants will distinguish between just two positions. If they reliably answer correctly, increase up to five points and integrate speed and dexterity in functional movements. Participants will be asked to relax and feel the movement during this training. Discrimination exercise: The therapist places a part of the participant's limb, the fingertip, on an external object (a block) and the participant will be asked to actively move his or her limb over the object and try to sense the shape of the object. If the participants differentiate between the two objects, then increase the number of objects (up to five). Functional training: The patient reaches toward many objects functionally (cup, ball, cane) from different angles, holds them, and relocates them again.
Study NCT06251661 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected traditional physical therapy program.
Description: The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
Study NCT06251661 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: selected traditional physical therapy program.
Description: The selected physical therapy program session will be occupational therapy training for the hand, strengthening exercises for the weak upper limb stretching exercises for short upper limb muscles, balance exercise, and gait training.
Study NCT06672809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Core Stability Training
Description: Participants in this group undergo core stability training sessions targeting deep stabilizing muscles. The exercises are designed to enhance spinal support and core control by activating the transversus abdominis and other core muscles. Sessions involve the use of a Pilates reformer and other unstable surfaces, fostering proprioceptive engagement and improved muscle coordination. Training is conducted three times per week for eight weeks, with each session lasting 50 minutes.
Study NCT04646889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Single Dose
Description: A single dose of AR882
Study NCT06679985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casdozokitug
Description: Solution for infusion
Study NCT04646889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR882 Multiple Dose
Description: AR882 taken once daily for 14 days
Study NCT05286281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07265803
Description: PF-07265803 is a p38 inhibitor formulated for oral delivery.
Study NCT05195970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: Participants consume 2 ounces of walnuts daily for 21 days
Study NCT06679985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Solution for infusion
Study NCT04819646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Marine Lipid Oil Concentrate Formulation
Description: Marine Lipid Oil Concentrate softgels
Study NCT04819646 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Supplement
Description: Dietary Supplement capsules
Study NCT04840615 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LMB-100
Description: LMB-100 administered into lesion on days 1 and 4 during cycle 1.
Study NCT04840615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Administered intravenously once per cycle up to three 21-day cycles. Administration will occur during cycles 2,3,4.
Study NCT05808205 — intervention group
Intervention type: DEVICE
Intervention: • ALIAXIN EV: Essential Volume • ALIAXIN FL: Lips • ALIAXIN SR: Shape & Restore • ALIAXIN GP: Global Performance • ALIAXIN LV: Lips Volume
Description: According the investigator judgment and IP' Instruction For Use (IFU), each subject can be treated in one or more of following face area:~* Temporal / frontal area~* Orbital / Malar area~* Perioral area~* Lips.
Study NCT06679985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Toripalimab
Description: Solution for infusion
Study NCT06679985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Solution for infusion
Study NCT06679985 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Solution for infusion
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDE196
Description: Dosed orally, twice daily
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Dosed orally, twice daily
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV administration every 3 weeks
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: IV administration every 3 weeks for 4 Cycles
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: IV administration every 3 Weeks for 4 Cycles, thereafter every 4 Weeks maintenance
Study NCT05987332 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: IV administration every 3 Weeks
Study NCT06252649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI Regimen
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
Study NCT06252649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI Regimen
Description: Combination of irinotecan, leucovorin, and 5-fluorouracil given intravenously Q2W.
Study NCT06252649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Immediate-release solid dosage form administered PO.
Study NCT06672809 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants in this group engage in aerobic exercise sessions that consist of warm-up, controlled-intensity walking, and a cool-down phase. This intervention serves as a comparative baseline, aiming to improve cardiovascular endurance without specifically targeting core stability. The aerobic routine is adjusted over time to increase exercise intensity, conducted three times per week for eight weeks, with each session lasting 50 minutes.
Study NCT04758884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Visits by videoconference in months 0, 1, 2, 3, 4 and 6.
Study NCT06252649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Administered IV Q2W.
Study NCT04840615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Infusion related reactions precaution: All participants will be premedicated with 25-50 mg Diphenhydramine by mouth (PO) or intravenous (IV) (or alternative antihistamine at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
Study NCT04840615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Infusion related reactions precaution: All participants will be premedicated with 20 mg Famotidine by mouth (PO) or intravenous (IV) (or alternative histamine H2- receptor antagonists (H2) blocker at adequate dose) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
Study NCT04840615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Infusion related reactions precaution: All participants will be premedicated with 650 mg Acetaminophen by mouth (PO) or intravenous (IV) 30-60 minutes (+ 30 minutes) prior to each LMB-100 administration.
Study NCT04840615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Additional infusion precaution at infusions of LMB-100 after Cycle 1 Day 1 (as appropriate): Dexamethasone 20 mg by mouth (PO), 6-12 hours prior to LMB-100 administration OR 10mg, intravenous (IV), 30-60 minutes prior to LMB-100 administration OR equivalent dose of another corticosteroid as clinically indicated.
Study NCT04840615 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: As feasible at screening, Cycle 1 Day 1 and 5, Cycle 2, 3, \& 4 Day 1, and Cycle 4 Day 21 (±7 days).
Study NCT06252649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab-awwb
Description: Administered IV Q2W.
Study NCT05583071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: IV
Study NCT05583071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral
Study NCT05583071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: IV
Study NCT05583071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific joint mobilization post muscle inhibition on C1
Description: Grasp the hand with the thumb or forefinger at the spinous process of C1. The contratoma hand is placed in forceps with the thumb and forefinger on the patient's temple, one on each side. Resisting with the hand on the temple, the therapist asks the patient to perform a 6-second isometric contraction of the cervical spine flexor muscles. The therapist then instructs the patient to relax the musculature and simultaneously performs posteroanterior pressure on the spinous process of C2 and passive extension of the head (with the hand on the temple). The maneuver is repeated until the therapist notices the release in the flexion-extension movement of the head.
Study NCT04840615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Maitland C2
Description: Maitland central posterior-anterior passive joint mobilization at C2: The patient will lie prone, the therapist behind the patient's head, with both thumbs will apply a central force on the spinous process of C2. The duration of the application will be up to five applications of 10 to 30 seconds in duration, depending on clinical judgment.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SNAG C1
Description: Sustained natural apophyseal slippage (SNAG) will be applied e.g. in the case of wanting to improve the left rotation. The therapist performs a sustained anterior glide to the C1 transverse process on the left. The participant will be seated, simultaneously rotating their head to the left while holding the SNAG. The glide of C1 will be maintained by the therapist until the participant's head returns to the neutral starting position. The same will be done, but in the opposite direction to improve the right rotation.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Specific joint mobilization post muscle inhibition on C2
Description: The therapist rotates the head to the right side until the final sensation of the movement is noted, either due to pain or muscular tension. From this position, the therapist asks the patient to rotate the head to the left side while offering resistance with both hands in the opposite direction, in such a way as to generate an isometric contraction of the rotator muscles of the head to the left. The therapist then asks the patient to hold the position for 6 seconds. Subsequently, the therapist with the finger in the transverse process of C1, pushes it in the postero-anterior direction and simultaneously (with the contratome hand) rotates the patient's head to the right. The technique is repeated until the ROM improves, always taking into account the patient's tolerance.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial inductions; Suboccipital induction
Description: The therapist places his hands under the patient's head in such a way that he can palpate the spinous processes of the cervical vertebrae with his fingers. Next, slowly bring your fingers up until they contact the occipital condyles. At this time he should gently move his fingers downward, thus finding the space between the condyles and the spinous process of the axis. Next, flexing the metacarpophalangeal joints to 90°, slowly elevate the skull. The therapist's hands should remain together and the base of the skull should rest on their palms. The therapist should apply pressure with the index, middle and ring fingers of each hand. This pressure should be maintained for a few minutes until a release of the fascia is noted. In the last phase of the technique, the therapist, without releasing the pressure, opens his hands and slowly brings his head back.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial inductions; Synchronization of the temporal bones PHASE 1
Description: The therapist rests his two forearms on the table, in such a way that he can contact the external auditory canal with his middle fingers. Place the ring fingers on the mastoid processes and the index fingers on the zygomatic arches. Subsequently, a rotary movement is made on the axis marked by the line that joins the middle fingers. With one of the hands, the movement is in the direction of movement clockwise, and with the other hand, simultaneously, in the opposite direction. By obtaining a symmetry in the movement in opposite directions, the movement is made in the same direction with both hands, first forwards and then backwards. Note how the ring fingers rotate first backwards and then upwards. Symmetry in movements should also be sought
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial inductions; Horizontal induction of the TMJ.
Description: The therapist places the middle fingers of both hands on the lingual aspect of the lower molar teeth and then gently presses towards the table. This pressure must be maintained for a minimum of 90 to 120 seconds. Afterwards, the therapist, very attentive to the changes in the direction of the fascial restriction, follows the release movement.
Study NCT04840615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT CAP
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
Study NCT04840615 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: At screening, at the end of cycles 2 \& 4 ± 7 days, Follow-Up Visit (4-6 weeks after end of treatment), and Long-Term Follow-Up (every 6-12 weeks).
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial inductions; Posterior elongation of the cervical fascia in the supine position
Description: Position of the patient, lying on the stretcher in the supine position. Therapist position: Sitting at the head of the table. Technique: With one of his hands, the therapist supports the patient's head on the occipital area and slowly brings it to flexo-elevation. With the other hand, he contacts the mass of the paravertebral muscles, placing the thumb on one side of the spine and the proximal interphalangeal joint of the index finger in flexion on the other. While one hand holds the head position, the other performs a downward vertical slide. The maneuver is repeated between 3 and 7 times in a slow and progressive manner.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial induction; Angle of the scapula
Description: Position of the patient, supine position, with the arm resting along the trunk. Position of the therapist, standing or sitting at the head of the table. The therapist places one of his hands under the shoulder blade, embracing the lower angle with the fingertips and bringing it slightly cranially. This maneuver frees access to the superior angle of the scapula, which makes it easier for the index and middle fingers of the other hand to contact the insertion of the angle. More sustained pressure is applied to this point, while the hand placed on the scapula moves in the direction of release.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial induction sternocleidomastoid muscles
Description: Objective, release the myofascial restrictions of the fascia of the SCM muscle. Position of the patient, supine position with the head near the upper edge of the stretcher. Therapist position. sitting at the head of the stretcher. Technique: The therapist, with one hand placed on the occipital region, gently rotates the patient's head. The other hand places it on the mass of the SCM muscle with the thumb at the point of insertion on the mastoid process. While one hand applies the rotational movement and a slight extension of the head, the other performs a transverse slide over the zone of restriction in the SCM muscle. A longitudinal sliding movement of the SCM muscle can be made between the thumb and forefinger of the executing hand.
Study NCT05447338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial induction of pectoralis major and minor
Description: Objective, release the fascia of the pectoralis major and minor muscle. Position of the patient, supine position, with the arm abducted to about 120 degrees. Position of the therapist, standing next to the patient, at head height. Technique: with his cranial hand, the therapist holds the patient's arm, and with the caudal hand, placed in a prone position, contacts the space between pectoralis major and ribs. This contact is made with the fingertips. The pressure should be maintained for about 5 minutes. As the release occurs, both of the therapist's hands must adjust to the direction of the changes. When detecting the restriction in the pectoralis minor, the penetration should be deepened with the hand, sliding it over the ribs. Contact and restraints with the pectoralis minor and major are often particularly painful, forcing the therapist to apply controlled force.